50 Pharmaceutical Technology BIOLOGICS AND STERILE DRUG MANUFACTURING 2019 P h a r mTe c h . c o m
lack of progress (21). In Europe, there may be
70 biosimilars by 2020, and then a second wave
of patent expirations will widen the available
armamentarium.
With the biosimilars marketed in Europe and
the US, the record of safety and efficacy has been
excellent thus far. It can be surmised that so far,
the regulatory process has appeared to be robust
enough to prevent clinical issues, even across use
of biosimilars by millions of patients. This bodes
well for the future of biosimilars.
References
1. FDA, Biosimilar and Interchangeable Products, FDA.gov, Up-
dated October 2017, www.fda.gov/Drugs/DevelopmentApprov-
a lProcess/HowDr ugsa reDevelopeda nd Approved /Approva-
lApplications/TherapeuticBiologicApplications/Biosimilars/
ucm580419.htm#biosimilar, accessed October 16, 2018.
2. Jacoby Rob, Biosimilars: Tapping the Potential of Emerging
Markets, Deloitte Blog, Aug. 24, 2015, http://blogs.deloitte.com/
centerforhealthsolutions/biosimilars-tapping-the-potential-of-
emerging-markets/, Accessed June 21, 2018.
3. E M A , E u r o p e a n P u b l i c A s s e s s m e nt R e p or t s , E M A . E u -
ropa .eu., w w w.ema .eu ropa .eu /med ici nes/f ield _ ema _web_
c at e gor ie s%2 53A n a me _ f ie ld / Hu m a n /e m a _ g roup_ t y p e s /
ema_medicine/field_ema_med_status/authorised-36/ema_medi-
cine_types/field_ema_med_biosimilar/search_api_aggregation_
ema_medicine_types/field_ema_med_biosimilar, Accessed 13
February 2019.
4. O. Kwon, et al., Biologicals 48 pp .101-108 (2017).
5. FDA, FDA-Approved Biosimilar Products, FDA.gov, www.fda.
gov/drugs/developmentapprovalprocess/howdrugsaredeveloped-
andapproved/approvalapplications/therapeuticbiologicapplica-
tions/biosimilars/ucm580432.htm, accessed July 5, 2018.
6. AG Vulto and OA Jaquez, Rheumatology, 56 (4) pp. iv14-19 (2017).
doi:10.1093/rheumatology/kex278
7. SK Singh, D. Kumar, and A.S. Rathore, AAPS, 19 (6) pp.1826-1841
(2017), doi:10.1208/s12248-017-0139-8.
8. GaBI, Comparison of EPARs for G-CSF Biosimilars Approved in
Europe, GaBI Journal. Generics And Biosimilar Initiative, Feb.
22, 2013, http://gabi-journal.net/news/comparison-of-epars-for-
g-csf-biosimilars-approved-in-europe, accessed June 21, 2018.
9. M. McCamish and G. Woollett, Clinical Pharmacology & Thera-
peutics, 93 (4) pp. 315–317 (2013). doi:10.1038/clpt.2013.17
10. B. Sharma, Biotechnol. Advances, 25 (3) pp. 325-331 (2007).
11. AJ Chirino and A. Mire-Sluis, Nat Biotechnol, 22 (11) pp.1383-
1391 (2004), doi:10.1038/nbt1030
12. N. Nupur et al., MAbs, 10 (1) pp. 143-158 (2018), doi:10.1080/194
20862.2017.1402996
13. N. Nupur et a l., J Chromatog r B, 1032 pp. 165-171 (2016),
doi:10.1016/j.jchromb.2016.05.027
14
. A. Covic and MK Kuhlmann, Int Urol Nephrol, 39 (1) (2007),
pp.261-266. doi:10.1007/s11255-006-9167-5
15. C.L. Bennett, et al. N Engl J Med. 351 (14) pp. 1403-1408 (2004),
doi:10.1056/NEJMoa040528
16. EMA, Pharmacovigilance–EudraVigilance, www.ema.europa.
eu, www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/
general/general_content_000679.jsp., accessed June 21, 2018.
17. FDA, MedWatch: The FDA Safety Information and Adverse Event
Reporting Program, www.fda.gov/Safety/MedWatch/default.htm,
accessed June 21, 2018.
18. FDA, Nonproprietary Naming of Biological Products, Guidance
for Industry (CDER, 2017).
19. D. Tomaszewski, J Manag Care Spec Pharm, 22 (8) pp. 919-926
(2016), www.jmcp.org/doi/pdf/10.18553/jmcp.2016.22.8.919, Ac-
cessed June 21, 2018.
20. Eu ropea n Com mission, Interna l Ma rket, Indust r y, Ent re-
preneu rsh ip a nd SM E s , Fou r t h St a keholder C on ferenc e
on Biosimilars, ht tp://ec.europa.eu/research/hea lt h/index.
cfm?pg=policy&policyname=global_forum, accessed April 29,
2019.
21. J. Wechsler, "FDA's Gottlieb Hits Innovators, Insurers for Block-
ing Biosimilar Uptake," PharmExec.com, March 8, 2018, www.
pharmexec.com/fda-s-gottlieb-hits-innovators-insurers-block-
ing-biosimilar-uptake.
22. E. Moorkens et al., PLoS ONE, 12 pp.1-17 (2017), https://doi.
org/10.1371/journal.pone.0190147
23. V. Razanskaite et al., Journal of Crohn's and Colitis, 11 pp.690–
696 (2017), https://doi.org/10.1093/ecco-jcc/jjw216
24. L.E., Kristensen et al., Biodrugs, 32 pp.397-404 (2018), https://
link.springer.com/article/10.1007%2Fs40259-018-0306-1
25. EMA, What I need to know about Biosimilar Medicines–In-
formation for patients, http://ec.europa.eu/DocsRoom/docu-
ments/26643, accessed July 5, 2018.
PT
Biosimilars
AMRI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
CATALENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
CONTEC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
EMERGENT BIOSOLUTIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
LONZA BIOLOGICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
PATHEON PHARMACEUTICAL SERVICES INC . . . . . . . . . . . . . . . . . . . . 25
PERFEX CORP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
SARTORIUS STEDIM NA INC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
VELTEK ASSOCIATES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Ad Index
COMPANY PAGE
